Navigation Links
Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/28/2008

SAN DIEGO, April 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008 at 9:50 a.m. Eastern Time (6:50 a.m. Pacific Time) at the Ritz-Carlton in Key Biscayne, Florida. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Students interested ... Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have ... competition begins Feb. 1, and the deadline is May 31, with the winner announced ...
(Date:1/19/2017)... Pittsburgh, PA (PRWEB) , ... January 19, 2017 , ... ... the experience of patients who seek access to the Network’s programs and services in ... requesting primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
(Date:1/19/2017)... ... ... The 21st Century Cures Act’s Impact on Medical Devices:, What You Need ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do manufacturers ... year? , The passage of the act means devicemakers will be scrambling to meet ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... -- The global  pacemaker market  is expected to reach USD 12.3 ... The heightening prevalence of cardiac conditions coupled with the availability of medical coverage ... technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: